Introduction Hemophilia comprises a group of X-linked hemorrhagic disorders that result
from a deficiency of coagulation factors. The disorder affects mainly males and leads to …

Aim To determine the immunogenicity, safety, and efficacy of rurioctocog alfa pegol in
previously untreated patients (PUPs) with severe hemophilia A (HA). Methods This …

Plasma-derived therapeutic proteins are produced through an industrial fractionation
process where proteins are purified from individual intermediates, some of which remain …

Antibody inhibitor development in hemophilia A represents the most significant complication
resulting from factor VIII (fVIII) replacement therapy. Recent studies have demonstrated that …

Background Recurrent hemarthrosis is one of the major complications affecting joint
functions, and causing chronic pain in hemophilia patients. Objective To summarize the …

Background and aim Treating hemophilia A patients who develop inhibitors remains a
clinical challenge. A mouse model of hemophilia A can be used to test the efficacy of …

Hemophilia A, the most common hereditary disorder, is caused by clotting factor deficiency.
Challenges encountered in the current treatment of hemophilia A [factor VIII (FVIII) …

Hemophilia is a recessive genetic disease caused by a mutation on the X chromosome that
has been linked to a high risk of transfusion-transmitted infections, especially sexually …

Background Patients with Hemophilia are continually monitored at treatment centers to
avoid and control bleeding episodes. This study estimated the direct and indirect costs per …

Background Prediction of inhibitor development in patients with hemophilia A (HA) remains
a challenge. Aim To construct a predictive model for inhibitor development in HA using a …